Maryland — The Maryland Department of Health is warning residents about the growing presence of xylazine in the state’s street drug supply as overdose deaths involving the substance continue to rise. The veterinary sedative, which is not approved for human use, is increasingly being found in combination with fentanyl, significantly increasing the risk of fatal drug interactions. Xylazine, commonly known as “tranq,” causes heavy sedation, slowed breathing, and severe skin ulcerations. It does not respond to naloxone, the standard treatment for opioid overdoses, making it more difficult for first responders to reverse the effects in emergency situations. Health officials report that xylazine has been identified in a growing number of toxicology reports from fatal overdoses across Maryland. In response, the state has launched a public awareness campaign to inform residents of the health risks and encourage caution. The website StopOverdose.maryland.gov/xylazine provides information on how the drug works, its health impacts, and steps to reduce harm. The campaign is part of a broader strategy to curb the rising number of overdose deaths and expand access to education and treatment. The department is urging Marylanders to remain alert to changes in the drug supply and to take steps to protect themselves and their communities. Residents experiencing a crisis or seeking recovery support are encouraged to call or text 988. The helpline connects individuals with trained professionals who can provide immediate assistance, referrals, and emotional support.
